The studies investigated a total of 18 parameters including, sex, age, ethnicity, height, body weight, low-dose AHT or monotherapy, severity HT at 5–6 years previous to study, BP levels before withdrawal, duration AHT, lower sodium levels, lower corpuscular volume, higher serum albumin, baseline alcohol or cigarette use, history of vascular disease, baseline of left ventricular mass index, baseline ECG voltage and cardiovascular risk factors. This evidence concerns the gene ALB and hematocrit.